Abstract
Aim:
To characterize and compare the different biological behaviors of 2 novel human osteosarcoma cell lines, Zos and Zos-M, established respectively from the primary tumor and the skip metastasis of an osteosarcoma patient.
Methods:
In vitro studies included morphological observations, karyotype analysis, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation assay, and cell sensitivity to chemotherapeutic drugs. Subcutaneous and intravenous inoculations into nude mice were carried out to study the tumorigenicity and the metastatic potential. RT-PCR was performed to assess the expression of the osteoblastic markers and some metastasis-related genes.
Results:
Both cell lines remained stable for more than 100 passages in vitro without interruption. The RT-PCR examination indicated that they retained the molecular characteristics of an osteoblastic lineage. The karyotype analysis displayed aneuploidy and various structural abnormalities. Both cell lines are tumorigenic; Zos-M differs from Zos by the former's ability to develop lung metastasis after intravenous injection. The comparison of the expression patterns of some metastasis-related genes revealed that the decreased expression of cadherin-11 in Zos-M may correlate with a high potential of metastases. Moreover, both cell lines are less sensitive to the current chemotherapy protocols.
Conclusion:
The establishment of osteosarcoma cell lines, Zos and Zos-M, and related animal models provide a useful resource for studying the aggressive behavior of osteosarcoma and will be helpful for screening effective treatment strategies.
Similar content being viewed by others
Article PDF
References
Link MP, Eilber F . Pediatric oncology: osteosarcoma. In: Pizzo P A, Poplack DG. editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott; 1989. p 689–711.
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776–90.
Bruland OS, Pihl A . On the current management of osteosarcoma: a critical evaluation and a proposal for a modifed treatment strategy. Eur J Cancer 1997; 33: 1725–31.
Enneking WF, Kagan A . The implications of “skip” metastases in osteosarcoma. Clin Orthop 1975; 111: 33–41.
Malawer MM, Dunham WK . Skip metastases in osteosarcoma: Recent experience. J Surg Oncol 1983; 22: 236–45.
Sajadi KR, Heck RK, Neel MD, Rao BN, Daw N, Rodriguez-Galindo C, et al. The incidence and prognosis of osteosarcoma skip metastases. Clin Orthop Relat Res 2004; 426: 92–6.
Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, Kotz R, et al. Cooperative Osteosarcoma Study Group. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2006; 24: 1535–41.
Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL Jr . Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymicmice. Cancer Res 1993; 53: 4890–5.
Fournierf, B Price, P A . Characterization of a new human osteosarcoma cell line OHS-4 J Cell Biol 1991; 114: 577–83.
Narita M, Nomura J, Nakase M, Inui M, Murata T, Hamaguchi Y, et al. Characterization of the human mandibular osteoblastic osteosarcoma cell line HOSM-2 after long-term culture. Oral Oncol 2004; 40: 742–50.
Kimura K, Nakano T, Park YB, Tani M, Tsuda H, Beppu Y, et al. Establishment of human osteosarcoma cell lines with high metastatic potential to lungs and their utilities for therapeutic studies on metastatic osteosarcoma. Clin Exp Metastasis 2002; 19: 477–85.
Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998; 76: 418–22.
Kashima T, Nakamura K, Kawaguchi J, Takanashi M, Ishida T, Aburatani H, et al. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 2003; 104: 147–54.
Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K . Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 2003; 20: 525–9.
Fukaya Y, Ishiguro N, Senga T, Ichigotani Y, Sohara Y, Tsutsui M, et al. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol Rep 2005; 14: 847–52.
Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001; 61: 3750–9.
Sandberga AA, Bridgeb JA . Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003; 145: 1–30.
Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, Link MP . Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol 1991; 9: 600–5.
Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001; 37: 32–8.
Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, et al. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the cooperative osteosarcoma study group (COSS). J Clin Oncol 2005; 23: 559–68.
Giuliano A, Feig S, Eilber FR . Changing metastatic pattern in osteosarcoma. Cancer 1984; 54: 2160–4.
Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710–5.
Greene FL, Page DL, Fleming ID . AJCC cancer staging manual, 6th ed. New York: Springer-Verlag; 2002.
Wuisman P, Enneking WF . Prognosis for patients who have osteosarcoma with skip metastasis. J Bone Joint Surg 1990; 72A: 60–8.
Kashima T, Kawaguchi J, Takeshita S, Kuroda M, Takanashi M, Horiuchi H, et al. Anomalous cadherin expression in osteosarcoma possible relationships to metastasis and morphogenesis. Am J Pathol 1999; 155: 1549–55.
Pujuguet P, Del Maestro L, Gautreau A, Louvard D, Arpin M . Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell 2003; 14: 2181–91.
Choi SH, Takahashi K, Eto H, Yoon SS, Tanabe KK . CD44s expression in human colon carcinomas infuences growth of liver metastases. Int J Cancer 2000; 85: 523–6.
Pereira PA, Rubenthiran U, Kaneko M, Jothy S, Smith AJ . CD44s expression mitigates the phenotype of human colorectal cancer hepatic metastases. Anticancer Res 2001; 21: 2713–7.
Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, et al. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 2005; 11: 3309–14.
Lafeur EA, Koshkina N V, Stewart J, Jia SF, Worth LL, Duan X, et al. Increased fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004; 10: 8114–19.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Natural Science Foundation of China (No 30200285) and the Sun Yat-Sen University 5010 grant.
Rights and permissions
About this article
Cite this article
Zou, Cy., Wang, J., Shen, Jn. et al. Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases. Acta Pharmacol Sin 29, 325–332 (2008). https://doi.org/10.1111/j.1745-7254.2008.00756.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00756.x
Keywords
This article is cited by
-
Prognostic and predictive value of super-enhancer-derived signatures for survival and lung metastasis in osteosarcoma
Journal of Translational Medicine (2024)
-
Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma
Nature Cell Biology (2020)
-
Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway
Cell Death & Disease (2018)
-
MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1
Oncogene (2017)